Female mice liberated for inclusion in neuroscience and biomedical research.
Level 5 - mechanism / opinion, no new human data
Preclinical meta-analysis of animal (mouse) studies (Level 5 under clinical CEBM framework)
PubMed 24456941 · doi:10.1016/j.neubiorev.2014.01.001
What was done
Meta-analysis of 293 published articles comparing trait variability between male mice and female mice tested without regard to estrous cycle stage. The analysis evaluated variability across behavioral, morphological, physiological, and molecular endpoints, as well as the impact of group housing.
What was found
Variability was not significantly greater in unstaged female mice compared to male mice for any evaluated endpoint, and males showed substantially greater variability for several traits. Group housing increased variability across both sexes by 37%. Specific trait-by-trait metrics, standard deviations, and exact p-values were not reported in the abstract.
Why it matters
This study refutes the assumption that female mice are inherently more variable than males due to estrous cycles. It demonstrates that female rodents can be routinely included in biomedical research protocols without requiring cycle staging.
Limits
The abstract reports no exact numeric values, effect sizes, or confidence intervals for the trait comparisons. The findings are derived entirely from preclinical mouse literature and cannot be directly extrapolated to human clinical physiology, and the analysis is subject to publication bias in the underlying animal literature.
Cited by
- supports Historically, most biomedical and clinical trial research was conducted primarily on males because of concerns regarding greater physiological variability in females.